JACC: Advances (Sep 2024)

Atrial Fibrillation in Hypertrophic Cardiomyopathy

  • Adaya Weissler-Snir, MD, MSc,
  • Sara Saberi, MD,
  • Timothy C. Wong, MD,
  • Antonis Pantazis, MD,
  • Anjali Owens, MD,
  • Alexander Leunig, MD,
  • Chikezie Alvarez, MD,
  • Florian Rader, MD, MSc

Journal volume & issue
Vol. 3, no. 9
p. 101210

Abstract

Read online

Atrial fibrillation (AF) is common among patients with hypertrophic cardiomyopathy (HCM) with a prevalence greater than 25%. AF in HCM is associated with a high risk of stroke and can be a marker of more advanced cardiomyopathy. Although, it frequently results in cardiac hemodynamic changes which are poorly tolerated, it can be subclinical. Thus, prompt diagnosis and adequate management of AF are essential to minimizing AF-related adverse outcomes in HCM. All HCM patients should be screened for AF regularly, and those with high-risk features should be screened more frequently preferably with extended ambulatory monitoring. Once AF is detected, oral anticoagulation should be initiated. Both general and HCM-specific modifiable risk factors should be addressed and assessment for cardiomyopathy progression should be performed. Although no randomized controlled studies have compared rate versus rhythm control in HCM, early rhythm control could be considered to prevent further LA remodeling.

Keywords